Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study

BACKGROUND: For advanced gastric cancer (GC) patients who fail first-line treatment, chemotherapy alone is of limited benefit. Ramucirumab combined with paclitaxel and apatinib combined with docetaxel provided clinical benefit in previous studies, but the feasibility of apatinib combined with other...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yan, Xu, Junying, Wang, Qiong, Ling, Guohong, Mao, Yong, Cai, Maohuai, Yang, Yang, Mei, Jingfeng, Han, Zhengxiang, Feng, Jifeng, Wu, Yuan, Shi, Lin, Wen, Shaodi, Shen, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263772/
https://www.ncbi.nlm.nih.gov/pubmed/35813347
http://dx.doi.org/10.21037/atm-22-2752

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263772/
https://www.ncbi.nlm.nih.gov/pubmed/35813347
http://dx.doi.org/10.21037/atm-22-2752

Ejemplares similares